Tags: Drug.
Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody designed for the treatment of pancreatic cancer. The antibody itself clivatuzumab is conjugated with tetraxetan a chelator for yttrium-90 a radioisotope which destroys the tumour cells.The drug was developed by Immunomedics Inc.